Weight-Loss Drug Market Heats Up as Prices Drop and New Treatments Emerge
Novo Nordisk and Eli Lilly face new competition from Amgen's monthly injectable, shaking up the obesity treatment landscape.
Overview
- Novo Nordisk increases Wegovy's U.S. patient base with price cuts amid rising competition from Eli Lilly and emerging contenders.
- Amgen's stock surges on promising early results for MariTide, a monthly GLP-1 weight-loss injection, setting the stage for a market shift.
- Eli Lilly and Novo Nordisk report supply constraints and price reductions for popular weight-loss drugs as demand continues to rise.
- Federal Trade Commission scrutinizes Novo Nordisk's pricing strategies, potentially paving the way for generic versions of Ozempic and Wegovy.
- Investors react to the evolving market dynamics, with significant stock fluctuations for major pharmaceutical companies.